Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Split, Inactivated, Trivalent Influenza Vaccine Clear all

Conditions: Influenza
Interventions: Vero cell derived, trivalent, seasonal influenza vaccine, Licensed egg-derived, trivalent seasonal influenza vaccine; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 3,208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Mobile, Alabama • Tucson, Arizona • Sacramento, California + 25 more

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 817 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more

Conditions: Influenza
Interventions: Split, Inactivated, Trivalent Influenza vaccine (Fluzone®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV); Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,928 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 20
States / cities: Chandler, Arizona • Anaheim, California • Paramount, California + 17 more

Conditions: Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,098 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more

Conditions: Influenza
Interventions: High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 1,180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Influenza Virus Vaccine USP Trivalent Types A and B; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 4,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 46
States / cities: Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 40 more

Conditions: Atopic Dermatitis
Interventions: Fluzone® Intradermal (Sanofi Pasteur Inc.); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Influenza
Interventions: Fluzone® (IM), Fluzone®; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Sacramento, California • San Diego, California + 31 more

Conditions: Influenza
Interventions: CSL's Influenza Virus Vaccine (Afluria), Influenza Virus Vaccine (Fluzone); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 1,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 23
States / cities: Chandler, Arizona • Harrisburg, Arkansas • Jonesboro, Arkansas + 16 more

Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions: Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Stanford, California • Torrance, California • Iowa City, Iowa + 7 more

Conditions: Influenza, Orthomyxovirus Infection, Myxovirus Infection
Interventions: Influenza Virus Vaccine USP Trivalent Types A and B; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 28
States / cities: Hoover, Alabama • Mobile, Alabama • Chandler, Arizona + 24 more

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 520 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 19
States / cities: Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more

Conditions: Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions: Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza
Interventions: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline; Biological · Other
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 3,670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 34
States / cities: Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more

Search by objective public record fields.

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

Immunogenicity and Safety of Different Doses of Fluzone® Influenza

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Comparison of Delivery Routes of Flu Vaccine in Adults

Influenza Vaccine Revaccination in Ambulatory Elderly Subjects

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)